⌘K
Loading ticker…
Altimmune, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Altimmune, Inc. Common Stock (ALT) has a 3-month relative strength percentile of 24 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 39. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.5%, relative volume 4.69×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
24 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ALT is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -3.5% / -27.1%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
ALT is held by 6 ETFs as of Mar 2026. Top owner: XBI at 0.18% weight, $13M notional. Top 3 carry $36M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | 0.18% | $13M |
| VTIVanguard Total Stock Market ETF | 0.00% | $13M |
| IWMiShares Russell 2000 ETF | 0.01% | $10M |
| VXFVanguard Extended Market ETF | 0.01% | $4M |
| IWOiShares Russell 2000 Growth ETF | 0.03% | $3M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $607K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALT Jan avg: 3.51% median: -12.00% win: 25% σ: 34.65% n: 4 2022-04-12 → 2026-05-29 | ALT Feb avg: -0.60% median: -3.77% win: 50% σ: 21.47% n: 4 2022-04-12 → 2026-05-29 | ALT Mar avg: -33.92% median: -26.67% win: 0% σ: 22.35% n: 4 2022-04-12 → 2026-05-29 | ALT Apr avg: -9.57% median: -15.58% win: 40% σ: 21.91% n: 5 2022-04-12 → 2026-05-29 | ALT May avg: 5.47% median: 11.95% win: 80% σ: 15.16% n: 5 2022-04-12 → 2026-05-29 | ALT Jun avg: 19.61% median: -12.04% win: 25% σ: 74.83% n: 4 2022-04-12 → 2026-05-29 (current) | ALT Jul avg: -3.15% median: -4.51% win: 25% σ: 3.95% n: 4 2022-04-12 → 2026-05-29 | ALT Aug avg: 17.36% median: 4.57% win: 75% σ: 46.27% n: 4 2022-04-12 → 2026-05-29 | ALT Sep avg: -12.33% median: -4.96% win: 25% σ: 20.41% n: 4 2022-04-12 → 2026-05-29 | ALT Oct avg: 2.02% median: 2.81% win: 50% σ: 7.98% n: 4 2022-04-12 → 2026-05-29 | ALT Nov avg: 16.87% median: 28.51% win: 75% σ: 25.07% n: 4 2022-04-12 → 2026-05-29 | ALT Dec avg: 68.53% median: 24.73% win: 50% σ: 131.99% n: 4 2022-04-12 → 2026-05-29 |